On October 7, 2021 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, reported that the immunotherapeutic capabilities of its DPX delivery platform will be featured in two e-poster presentations at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) October 7-10, 2021 (Press release, IMV, OCT 7, 2021, View Source [SID1234590935]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Collectively, these data demonstrate the versatility and potential of the DPX delivery platform to educate robust, targeted T cell responses to distinct cargo," said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV. "More specifically, the first presentation provides compelling evidence that the DPX technology triggers a more consistent and persistent immune response than conventional emulsions. The second presentation provides the scientific basis for the clinical pursuit of DPX-SurMAGE, a new IMV asset designed to simultaneously elicit immune responses to the survivin and MAGE-A9 proteins, both of which have been implicated in bladder cancer progression."

Yves Fradet, M.D., Professor, Department of Surgery at the Faculty of Medicine, Université Laval in Quebec City commented, "The results obtained with IMV’s dual-targeted DPX-based immunotherapy, DPX-SurMAGE, in preclinical studies are very promising. I believe that patients with bladder cancer will benefit from this treatment while maintaining their quality of life."

Pre-clinical and clinical data presented at the conference show that:

The DPX technology represents a versatile delivery platform that generates robust T cell-based immune responses,
When packaged within the DPX platform, antigenic peptides are delivered and presented to the immune system in a manner that elicits specific T cell-based immune responses that are not achievable with conventional water-based emulsion delivery,
IMV’s lead compound, maveropepimut-S (MVP-S, previously known as DPX-Survivac) is well-tolerated in multiple clinical trials and effectively elicits a specific, robust, and persistent, survivin-specific T cell response evident most prominently in subjects showing greatest clinical benefit,
The DPX delivery platform can be leveraged to incite a T cell response to numerous tumor antigens simultaneously,
IMV’s dual-targeted immunotherapy, DPX-SurMAGE, is well tolerated and generates robust and targeted T cell responses against both survivin and MAGE-A9 peptides in preclinical models.
Collectively, these data provide evidence that the DPX delivery platform is a unique and versatile, immune-educating technology that can be applied in a variety of therapeutic areas where generation of a target-specific immune response is expected to mitigate disease.

Poster Presentation Details

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients.

Presenter: Yogesh Bramhecha, Ph.D.,
Director, Translational Research, IMV Inc.
Poster Number: LBA026
DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical studies

Presenter: Yves Fradet, M.D.
Professor, Department of Surgery
Faculty of Medicine, Université Laval, Quebec City
Poster Number: LBA030
Full abstracts and e-posters are available on demand on the conference platform. Both e-posters are available under the Scientific Publications & Posters section on IMV’s website.